Cutaneous T-Cell Lymphoma (CTCL) Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Cutaneous T Cell Lymphoma (CTCL) / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphomas / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05956041Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasTreatment